CLVS earnings call for the period ending March 31, 2019.
News & Analysis: Clovis Oncology
The company decided to discontinue an important clinical trial.
Better-than-expected Rubraca sales were just what investors wanted to see.
CLVS earnings call for the period ending December 31, 2018.
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?
The down-on-its-luck pharma company turned in a solid year of growth. Will it be enough to remain competitive -- or find a suitor?
With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.
If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
GlaxoSmithKline's first major pharma acquisition in years isn't a hit with shareholders.
Three separate unfavorable events sent investors packing. Were things really that bad?